Steven A Rosenberg Selected Research

Neoplasms (Cancer)

09/2008	Cancer immunotherapy.
09/2008	Overcoming obstacles to the effective immunotherapy of human cancer.
06/2008	Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
04/2008	Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
11/2007	Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.
09/2007	Toll-like receptors in tumor immunotherapy.
04/2007	IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells.
10/2006	Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
05/2006	Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
03/2006	IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
12/2005	Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
11/2005	Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
05/2005	The emergence of modern cancer immunotherapy.
05/2005	TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.
03/2005	CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
03/2005	Cancer immunotherapy comes of age.
09/2004	Cancer immunotherapy: moving beyond current vaccines.
08/2004	Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.
07/2004	Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
05/2004	Development of effective immunotherapy for the treatment of patients with cancer.
04/2004	Shedding light on immunotherapy for cancer.
02/2004	IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
01/2004	Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
09/2003	High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
07/2003	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
05/2003	Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
05/2003	Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research.
05/2003	Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
02/2003	Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
09/2002	Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.
06/2002	The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy.
05/2002	A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
05/2002	Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells.
03/2002	Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy.

Articles by Research Topic

Disease

34	Neoplasms (Cancer) 09/2008 - 03/2002
27	Melanoma (Melanoma, Malignant) 09/2008 - 01/2002
3	Kidney Neoplasms (Kidney Cancer) 09/2007 - 07/2003
1	Enteritis 11/2007
1	Enterocolitis 05/2006
1	Uveitis 11/2004
1	Renal Cell Carcinoma (Grawitz Tumor) 07/2004
1	Colorectal Neoplasms (Colorectal Cancer) 10/2003
1	Hypercalcemia (Milk Alkali Syndrome) 02/2003
1	Waardenburg's Syndrome (Waardenburg Syndrome) 06/2002
1	Neoplasm Metastasis (Metastasis) 01/2002

Drug/Important Bio-Agent (IBA)

24	AntigensIBA 06/2008 - 01/2002
11	Interleukin-2 (IL2)IBA 09/2008 - 01/2002
6	cytotoxic T-lymphocyte antigen 4IBA 07/2008 - 07/2003
3	VaccinesIBA 09/2008 - 09/2004
2	Interleukin-15 (Interleukin 15)IBA 04/2007 - 02/2004
2	EpitopesIBA 11/2004 - 03/2004
2	bevacizumab FDA Link 07/2004 - 07/2003
2	PeptidesIBA 07/2003 - 05/2003
1	ipilimumabIBA 11/2007
1	Immunotoxins (Immunotoxin)IBA 10/2007
1	B3(Fv)-PE38KDEL recombinant immunotoxinIBA 10/2007
1	Toll-Like Receptors (Toll-Like Receptor)IBA 09/2007
1	Monophenol Monooxygenase (Tyrosinase)IBA 04/2006
1	Diphtheria ToxinIBA 11/2005
1	denileukin diftitox (Ontak)FDA Link 11/2005
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 05/2005
1	HLA-A*0201 antigenIBA 11/2004
1	Telomerase (Telomerase Reverse Transcriptase)IBA 07/2004
1	Thalidomide (Thalomid)FDA Link 07/2004
1	Glycoproteins (Glycoprotein)IBA 09/2003
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2003
1	DNA (Deoxyribonucleic Acid)IBA 05/2003
1	Immunodominant EpitopesIBA 05/2003
1	Parathyroid Hormone-Related ProteinIBA 02/2003
1	Differentiation AntigensIBA 11/2002
1	flt3 ligand protein (flt3 ligand)IBA 05/2002
1	Interferon-alpha (Interferon Alfa)FDA Link 03/2002
1	tyrosinase-related proteinIBA 01/2002

Therapy/Procedure

13	Immunotherapy 09/2008 - 01/2002
2	Drug Therapy (Chemotherapy) 04/2005 - 05/2002
1	Tissue Therapy (Cell Therapy) 05/2008
1	Therapeutics 05/2003